Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
Public ClinicalTrials.gov record NCT04547140. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) Plus Standard Medical Treatment (SMT) Versus Placebo Plus SMT in Hospitalized Subjects With COVID-19
Study identification
- NCT ID
- NCT04547140
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Enrollment
- 57 participants
Conditions and interventions
Conditions
Interventions
- Liquid Alpha1-Proteinase Inhibitor (Human) Biological
- Placebo Drug
- Standard Medical Treatment Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 28, 2021
- Primary completion
- Dec 12, 2021
- Completion
- Jan 27, 2022
- Last update posted
- Mar 21, 2023
2021 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Birmingham VA | Birmingham | Alabama | 35233 | — |
| St. Joseph's Hospital | Phoenix | Arizona | 85013 | — |
| University of Miami Hospital | Miami | Florida | 33125 | — |
| Sparrow Hospital | Lansing | Michigan | 48912 | — |
| Hannibal Clinic | Hannibal | Missouri | 63401 | — |
| Kansas City VA | Kansas City | Missouri | 64128 | — |
| CHI Health Center | Omaha | Nebraska | 68102 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Memphis VA | Memphis | Tennessee | 38104 | — |
| University of Utah | Salt Lake City | Utah | 84108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04547140, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 21, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04547140 live on ClinicalTrials.gov.